The influence of cardiac rehabilitation on inflammation and metabolic syndrome in women with coronary heart disease

Journal of Cardiovascular Nursing

Volumn 25, Issue 1, 2010, Pages 52-60

  Beckie, Theresa M ^a   Beckstead, Jason W ^a   Groer, Maureen W ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

C reactive protein (hsCRP); Cardiac rehabilitation; Inflammation; Intercellular adhesion molecule 1 (ICAM 1); Interleukin 6 (IL 6); Metabolic syndrome; Obesity; Tumor necrosis factor (TNF )

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUNSELING; EDUCATION; FEMALE; HUMAN; IMMUNOLOGY; INFLAMMATION; KINESIOTHERAPY; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MOTIVATION; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WOMEN'S HEALTH;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; COUNSELING; EXERCISE THERAPY; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; METABOLIC SYNDROME X; MIDDLE AGED; MOTIVATION; PATIENT EDUCATION AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOMEN; WOMEN'S HEALTH;

EID: 76649116891     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e3181b7e500     Document Type: Article

References (73)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statisticsV2009 update.AReport From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;119(3):e21-e181.
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752.
4. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97(2A):3A-11A.
5. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin EndocrinolMetab. 2007;92(2):399-404.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143-3421.
7. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887.
8. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-414.
9. Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis. 2007;195(2):e126-e134.
10. Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Impact of metabolic syndrome on atherosclerotic burden and cardiovascular prognosis. Am J Cardiol. 2007;99(12):1623-1628. (Pubitemid 46874314)
11. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005;2 8(10):2508-2513.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-397.
13. Yan E, Chen S, Hong K, et al. Insulin, hs-CRP, leptin, and adiponectin. An analysis of their relationship to the metabolic syndrome in an obese population with an elevated waist circumference. Metab Syndr Relat Disord. 2008;6(1):64-73.
14. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812-819.
15. Majka DS, Chang RW, Vu TH, et al. Physical activity and high-sensitivity C-reactive protein: the multi-ethnic study of atherosclerosis. Am J Prev Med. 2009;36(1):56-62.
16. Feinberg MS, Schwartz R, Behar S. Impact of metabolic syndrome in patients with acute coronary syndrome. Adv Cardiol. 2008;45:114-126.
17. Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46(3):464-469.
18. Albert MA, Glynn RJ, Ridker PM. Effect of physical activity on serum C-reactive protein. Am J Cardiol. 2004; 93(2):221-225.
19. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis. 2008;197(1):392-399.
20. Marroquin OC, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation. 2004;109(6):714-721.
21. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12):836-843. (Pubitemid 30165206)
22. Kip KE, Marroquin OC, Shaw LJ, et al. Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J. 2005;150(5):900-906.
23. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008;121(1):50-57.
24. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351(9096):88-92.
25. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis. 2008;200(1): 1-12.
26. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol. 2008;79(8 suppl):1544-1551.
27. Ridker P, Rifai N, Koenig W, Blumenthal RS. C-reactive protein and cardiovascular risk in the Framingham Study. Arch Intern Med. 2006;166(12):1327-1328.
28. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264(4):295-314.
29. Ogawa H, Yasue H,Miyao Y, et al. Plasma soluble intercellular adhesion molecule-1 levels in coronary circulation in patients with unstable angina. Am J Cardiol. 1999;83(1):38-42.
30. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43(6):1056-1061.
31. Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol. 2003;92(1):50-54.
32. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116(19): 2110-2118.
33. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45(10): 1563-1569.
34. Kelley GA, Kelley KS. Effects of aerobic exercise on C-reactive protein, body composition, andmaximumoxygen consumption in adults: a meta-analysis of randomized controlled trials. Metabolism. 2006;55(11):1500-1507.
35. Plaisance EP, Grandjean PW. Physical activity and highsensitivityC- reactive protein. Sports Med. 2006;36(5):443-458.
36. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682-692.
37. Wenger NK. Current status of cardiac rehabilitation. J Am Coll Cardiol. 2008;51(17):1619-1631.
38. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372. (Pubitemid 43947981)
39. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev. 2007;27(3):121-129.
40. Huffman KM, Samsa GP, Slentz CA, et al. Response of high-sensitivity C-reactive protein to exercise training in an at-risk population. Am Heart J. 2006;152(4):793-800.
41. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295(12):1412-1419.
42. Nicklas BJ, Hsu FC, Brinkley TJ, et al. Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc. 2008;56(11):2045-2052.
43. You T, Nicklas BJ. Effects of exercise on adipokines and the metabolic syndrome. Curr Diab Rep. 2008;8(1):7-11.
44. Lavie CJ, Morshedi-Meibodi A, Milani RV. Impact of cardiac rehabilitation on coronary risk factors, inflammation, and the metabolic syndrome in obese coronary patients. J Cardiometab Syndr. 2008;3(3):136-140.
45. Caulin-Glaser T, Falko J, Hindman L, La Londe M, Snow R. Cardiac rehabilitation is associated with an improvement in C-reactive protein levels in both men and women with cardiovascular disease. J Cardiopulm Rehabil. 2005; 25(6):332-336.
46. Kim YJ, Shin YO, Bae JS, et al. Beneficial effects of cardiac rehabilitation and exercise after percutaneous coronary intervention on hsCRP and inflammatory cytokines in CAD patients. Pflugers Arch. 2008;455(6):1081- 1088.
47. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol. 2005;100(1):93-99.
48. Ades PA, Savage PD, Toth MJ, et al. High-calorieexpenditure exercise. A new approach to cardiac rehabilitation for overweight coronary patients. Circulation. 2009; 119(20):2671-2678.
49. Beckie TM, Mendonca MA, Fletcher GF, Schocken DD, Evans ME, Banks SM. Examining the challenges of recruiting women into a cardiac rehabilitation clinical trial. J Cardiopulm Rehabil Prev. 2009;29(1):13-21.
50. Beckie TM. A behavior change intervention for women in cardiac rehabilitation. J Cardiovasc Nurs. 2006;21(2):146-153.
51. Beckie TM, Fletcher GF, Beckstead JW, Schocken DD, Evans ME. Adverse baseline physiological and psychosocial profiles of women enrolled in a cardiac rehabilitation clinical trial. J Cardiopulm Rehabil Prev. 2008;28(1):52-60.
52. Finley CE, LaMonte MJ,Waslien CI, Barlow CE, Blair SN, Nichaman MZ. Cardiorespiratory fitness, macronutrient intake, and the metabolic syndrome: the Aerobics Center Longitudinal Study. J Am Diet Assoc. 2006;106(5): 673-679.
53. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1995;91(2):580-615.
54. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002;106(14):1883-1892.
55. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.
56. Jackson AS, Pollock ML, Ward A. Generalized equations for predicting body density of women. Med Sci Sports Exerc. 1980;12(3):175-181.
57. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
58. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676-2681.
59. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-2304. (Pubitemid 41242486)
60. Helsel DR. More than obvious: better methods for interpreting nondetect data. Environ Sci Technol. 2005;39(20): 419A-423A.
61. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
62. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004; 109(23):2818-2825.
63. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16): 1955-1959.
64. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12(1): 38-48.
65. Miller WR, Rollnick S, eds. Motivational Interviewing: Preparing People for Change. 2nd ed. New York: Guilford; 2002.
66. Prochaska JO, Velicer WF, Redding C, et al. Stage-based expert systems to guide a population of primary care patients to quit smoking, eat healthier, prevent skin cancer, and receive regular mammograms. Prev Med. 2005;41(2):406-416.
67. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116(11): 1234-1241.
68. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versuswithout peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005;96(10):1374-1378.
69. Rahimi K, Secknus MA, Adam M, et al. Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2005;150(6):1282-1289.
70. Hamer M. The relative influences of fitness and fatness on inflammatory factors. Prev Med. 2007;44(1):3-11.
71. Lakka TA, Lakka HM, Rankinen T, et al. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J. 2005;26(19):2018-2025.
72. Ades PA, Savage PD, Brawner CA, et al. Aerobic capacity in patients entering cardiac rehabilitation. Circulation. 2006;113(23):2706-2712.
73. Genser B, Grammer TB, Stojakovic T, Siekmeier R, Marz W. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2008; 46(10):497-510.